Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Alexandra Gomez-Arteaga, Rory Shallis, Mariam Nawas, Landi Guo, Temitope Oloyede, Kwang Woo Ahn, Veronika Bachanova, Michael Byrne, Sergio Giralt, Lohith Gowda, Ann Jakubowski, Mark Litzow, Filippo Milano, Kristin Page, Wael Saber, Nelli Bejanyan, Larisa Broglie, Xinjie Xu, Jean Yared

Blood (2025) 146 (Supplement 1): 1060.

https://doi.org/10.1182/blood-2025-1060

Published: 2025

Journal Articles

CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH) – a matched cohort analysis by the center for international blood and marrow transplant research (CIBMTR) and the AIDS malignancy consortium (AMC)

Stefan Barta, Ariela Noy, Kwang Woo Ahn, Jinalben Patel, Tiffany Hunt, Uroosa Ibrahim, Robert Baiocchi, Deukwoo Kwon, Marcelo Pasquini, Richard Ambinder

Blood (2025) 146 (Supplement 1): 955.

https://doi.org/10.1182/blood-2025-955

Published: 2025

Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Blood (2025) 146 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2025-2400

Published: 2025

Journal Articles

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Blood (2022) 139 (9): 1330–1339.

https://doi.org/10.1182/blood.2021013289

Published: 2022

Includes: Supplemental data

Journal Articles

The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201

Nosha Farhadfar, Stephanie Bo-Subait, Kwang Woo Ahn, Brent R. Logan, Heather E. Stefanski, Jack W. Hsu, Sandhya R. Panch, Dennis L. Confer, Claudio Anasetti, Michael A. Pulsipher, Bronwen E. Shaw, John R. Wingard, Galen E. Switzer

Blood (2021) 138 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2021-151034

Published: 2021

Journal Articles

Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic

Steven Devine, Michelle Kuxhausen, Stephen R. Spellman, Caitrin Fretham, Kwang Woo Ahn, Heather E. Stefanski, Jeffery J. Auletta, Brent R. Logan, Bronwen E. Shaw

Blood (2021) 138 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2021-151445

Published: 2021

Journal Articles

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Muna Qayed, Kwang Woo Ahn, Carrie L. Kitko, Mariam H. Johnson, Nirali N. Shah, Christopher Dvorak, Karin Mellgren, Brian D. Friend, Michael R. Verneris, Wing Leung, Jacek Toporski, John Levine, Joseph Chewning, Alan Wayne, Urvi Kapoor, Brandon Triplett, Kirk R. Schultz, Gregory A. Yanik, Mary Eapen

Blood (2021) 137 (7): 983–993.

https://doi.org/10.1182/blood.2020009342

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Hemant S. Murthy, MD, Kwang Woo Ahn, PhD, Noel Estrada-Merly, MS, Lohith Gowda, MD, Bhagirathbhai Dholaria, MBBS, Susan Bal, MDMBBS, Hassan B. Alkhateeb, MD, Deepa Jagadeesh, MDMPH, Betul Oran, MDMS, Ryotaro Nakamura, MD, Bart L. Scott, MD, Craig S. Sauter, MD, Francine M. Foss, MD, Mohamed A kharfan-Dabaja, MDMBA, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134793

Published: 2020

Journal Articles

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Trent Wang, DO,MPH, Michael Scordo, MD, Kwang Woo Ahn, PhD, Stella Chen, MS, Mohamed A. Kharfan-Dabaja, MDMBA, Alex F. Herrera, MD, Mehdi Hamadani, MD, Craig S. Sauter, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-137237

Published: 2020

Journal Articles

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Sagar S. Patel, MD, Kwang Woo Ahn, PhD, Manoj Khanal, BS, MS, Caitrin Fretham, MPH, Celalettin Ustun, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Shin Mineishi, MD, Bipin N. Savani, MD, Mohamed Sorror, MD MSc, Edward A. Stadtmauer, MD FACP, Brent Logan, PhD, Marcelo C. Pasquini, MDMS, Saurabh Chhabra, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140503

Published: 2020

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Sairah Ahmed, MD, Nilanjan Ghosh, MD PhD, Manoj Khanal, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Timothy S. Fenske, MD, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 3318.

https://doi.org/10.1182/blood-2019-121848

Published: 2019

Journal Articles

Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?

Deepa Jagadeesh, MDMPH, Navneet S. Majhail, MD MS, He Yizeng, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Timothy S. Fenske, MD, Anna Sureda, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 785.

https://doi.org/10.1182/blood-2019-121347

Published: 2019

Journal Articles

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Betul Oran, MDMS, Kwang Woo Ahn, PhD, Caitrin Fretham, Mithun Vinod Shah, MD PhD, Ryotaro Nakamura, MD, Bart L. Scott, MD, Ronald Sobecks, MD, Uday Popat, MD, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 253.

https://doi.org/10.1182/blood-2019-121970

Published: 2019

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Nilanjan Ghosh, MD PhD, Sairah Ahmed, MD, Carlos Litovich, MPH, Kwang Woo Ahn, PhD, Manoj Khanal, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 319.

https://doi.org/10.1182/blood-2019-121849

Published: 2019

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Narendranath Epperla, MD, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Mohamed A Kharfan-Dabaja, MD, Sonali M. Smith, MD, Anna Sureda, MD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2018) 132 (Supplement 1): 969.

https://doi.org/10.1182/blood-2018-99-110469

Published: 2018

Journal Articles

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Haesook T Kim, PhD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Matthew Davids, MD, Virginia Volpe, MD, Edwin Alyea, MD, Uday Popat, MD, Ronald Sobecks, MD, Wael Saber, MD MS, Jennifer Brownn, MD PhD

Blood (2017) 130 (Supplement 1): 667.

https://doi.org/10.1182/blood.V130.Suppl_1.667.667

Published: 2017

Journal Articles

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Bei Hu, Xiao Lin, ^, Hans C. Lee, MD, Xuelin Huang, PhD, Rebecca Slack, MS, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Richard E Champlin, MD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Ying Lee, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 4582.

https://doi.org/10.1182/blood.V130.Suppl_1.4582.4582

Published: 2017

Journal Articles

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Saurabh Chhabra, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Sandeep Jain, MBBS, MRCP, Robert K. Stuart, MD, Matt Kalaycio, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, III, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 600.

https://doi.org/10.1182/blood.V130.Suppl_1.600.600

Published: 2017

Journal Articles

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

Brian T. Hill, MD PhD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Matt Kalaycio, MD FACP, Richard T. Maziarz, MD, Jorge E. Cortes, MD, Edwin Alyea, MD, Uday R. Popat, MD, Ronald M. Sobecks, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 2256.

https://doi.org/10.1182/blood.V128.22.2256.2256

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH) – a matched cohort analysis by the center for international blood and marrow transplant research (CIBMTR) and the AIDS malignancy consortium (AMC)

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201

Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Superiority of Thiotepa-Containing Conditioning Regimens in Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Undergoing Autologous Hematopoietic Cell Transplantation (autoHCT)

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only